Market open
Cytosorbents/$CTSO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cytosorbents
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Ticker
$CTSO
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
149
ISIN
US23283X2062
Website
Cytosorbents Metrics
BasicAdvanced
$52M
-
-$0.29
-
-
Price and volume
Market cap
$52M
52-week high
$1.61
52-week low
$0.70
Average daily volume
121K
Financial strength
Current ratio
2.61
Quick ratio
1.978
Long term debt to equity
182.24
Total debt to equity
185.499
Interest coverage (TTM)
-8.02%
Management effectiveness
Return on assets (TTM)
-20.46%
Return on equity (TTM)
-96.25%
Valuation
Price to revenue (TTM)
1.323
Price to book
3.59
Price to tangible book (TTM)
3.59
Price to free cash flow (TTM)
-3.425
Growth
Revenue change (TTM)
-3.69%
Earnings per share change (TTM)
-50.60%
3-year revenue growth (CAGR)
-5.04%
3-year earnings per share growth (CAGR)
-24.80%
What the Analysts think about Cytosorbents
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cytosorbents stock.
Cytosorbents Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cytosorbents Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cytosorbents News
AllArticlesVideos
Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 days ago
Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cytosorbents stock?
Cytosorbents (CTSO) has a market cap of $52M as of May 16, 2025.
What is the P/E ratio for Cytosorbents stock?
The price to earnings (P/E) ratio for Cytosorbents (CTSO) stock is 0 as of May 16, 2025.
Does Cytosorbents stock pay dividends?
No, Cytosorbents (CTSO) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Cytosorbents dividend payment date?
Cytosorbents (CTSO) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytosorbents?
Cytosorbents (CTSO) does not currently have a Beta indicator.